The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single-arm meta-analysis.
Ruijuan LiManqi HuaJiulong LiWeihong ChenLing XuHuan MengZhuo ZhangQianxin LiuYimin CuiQian XiangPublished in: Cancer (2024)
This comprehensive summary of the incidence of TEAEs associated with DS-8201 in clinical trials provides an important guide for clinicians. The most common TEAEs were gastrointestinal reactions and fatigue; meanwhile, the most common grade ≥3 TEAE was hematological toxicity. ILD and/or pneumonitis were specific adverse drug reactions associated with DS-8201, of which physicians should be particularly aware for their higher morbidity and rates of grade ≥3 TEAEs.
Keyphrases
- interstitial lung disease
- adverse drug
- systemic sclerosis
- systematic review
- rheumatoid arthritis
- clinical trial
- idiopathic pulmonary fibrosis
- primary care
- meta analyses
- emergency department
- palliative care
- risk factors
- oxidative stress
- epidermal growth factor receptor
- drug induced
- randomized controlled trial
- sleep quality
- study protocol
- double blind